stockrowAxsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +73.9%
- Free cash flow
- −1,078.3%
- Total debt
- +4.04%
Quarter to September 2026, against a year earlier
Follow AXSM
Alert me
Axsome Therapeutics, Inc. (AXSM) EPS (diluted)
Axsome Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$3.68, compared with −$5.99 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$3.06. Over the past ten years it has ranged from −$5.99 (fiscal 2024) to −$0.88 (fiscal 2015); the current reading is higher than 36% of that period. Axsome Therapeutics, Inc. ranks 377th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.68 | — |
| FY2024 | −$5.99 | — |
| FY2023 | −$5.27 | — |
| FY2022 | −$4.60 | — |
| FY2021 | −$3.47 | — |
| FY2020 | −$2.77 | — |
| FY2019 | −$2.01 | — |
| FY2018 | −$1.15 | — |
| FY2017 | −$1.27 | — |
| FY2016 | −$1.42 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.25 | — |
| Jun 2026 | −$0.99 | — |
| Mar 2026 | −$1.26 | — |
| Dec 2025 | −$0.56 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $2.24 |
| ORKA Oruka Therapeutics, Inc. compare | −$2.12 |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$2.73 |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −$2.89 |
| AXSM Axsome Therapeutics, Inc. | −$3.06 |
| IONS Ionis Pharmaceuticals, Inc. compare | −$3.46 |
| ABVX Abivax SA Sponsored ADR compare | −$6.06 |
| PRAX Praxis Precision Medicines, Inc. compare | −$12.93 |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$15.22 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on AXSM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement